443 related articles for article (PubMed ID: 19251818)
81. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
82. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
83. Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin.
Dong J; Gong Y; Liu J; Chen X; Wen X; Sun H
Bioorg Med Chem; 2014 Feb; 22(4):1383-93. PubMed ID: 24457090
[TBL] [Abstract][Full Text] [Related]
84. Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys.
Lin JH; Chiba M; Chen IW; Vastag KJ; Nishime JA; Dorsey BD; Michelson SR; McDaniel SL
J Pharmacol Exp Ther; 1995 Jul; 274(1):264-9. PubMed ID: 7616407
[TBL] [Abstract][Full Text] [Related]
85. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans.
Richter WF; Gallati H; Schiller CD
Drug Metab Dispos; 1999 Jan; 27(1):21-5. PubMed ID: 9884305
[TBL] [Abstract][Full Text] [Related]
86. Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation.
Maheen S; Rasul A; Hanif M; Khan HU
AAPS PharmSciTech; 2020 Jul; 21(5):188. PubMed ID: 32651896
[TBL] [Abstract][Full Text] [Related]
87. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.
Ericsson H; Tholander B; Björkman JA; Nordlander M; Regårdh CG
Drug Metab Dispos; 1999 May; 27(5):558-64. PubMed ID: 10220482
[TBL] [Abstract][Full Text] [Related]
88. Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats.
Zhu J; Hu Y; Ho MK; Wong YH
Xenobiotica; 2012 Nov; 42(11):1138-50. PubMed ID: 22642804
[TBL] [Abstract][Full Text] [Related]
89. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
90. The effects of probenecid upon the individual components of indomethacin elimination.
Duggan DE; Hooke KF; White SD; Noll RM; Stevenson CR
J Pharmacol Exp Ther; 1977 May; 201(2):463-70. PubMed ID: 404419
[TBL] [Abstract][Full Text] [Related]
91. Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.
Nishio Y; Kimura H; Tosaki S; Sugaru E; Sakai M; Horiguchi M; Masui Y; Ono M; Nakagawa T; Nakahira H
Bioorg Med Chem Lett; 2010 Dec; 20(24):7246-9. PubMed ID: 21074430
[TBL] [Abstract][Full Text] [Related]
92. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
93. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
[TBL] [Abstract][Full Text] [Related]
94. Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs.
Gu Y; Wang GJ; Sun JG; Jia YW; Wang W; Xu MJ; Lv T; Zheng YT; Sai Y
Food Chem Toxicol; 2009 Sep; 47(9):2257-68. PubMed ID: 19524010
[TBL] [Abstract][Full Text] [Related]
95. The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
Roy D; Chadwick KD; Tatarkiewicz K; LaCerte C; Bergholm AM; Brodie T; Mangipudy RS; Parkes D; Graziano MJ; Reilly TP
Diabetes Obes Metab; 2014 Oct; 16(10):910-21. PubMed ID: 24666399
[TBL] [Abstract][Full Text] [Related]
96. Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids. evidence that the dog is not a relevant species for evaluation of human health risk.
Timchalk C
Toxicology; 2004 Jul; 200(1):1-19. PubMed ID: 15158559
[TBL] [Abstract][Full Text] [Related]
97. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
[TBL] [Abstract][Full Text] [Related]
98. Dipeptidyl peptidase-4 inhibition prevents cell death via extrinsic and intrinsic apoptotic pathways in rat pancreas with insulin resistance.
Nephan G; Coskun ZM; Bolkent S
Cell Biochem Funct; 2018 Jun; 36(4):212-220. PubMed ID: 29748970
[TBL] [Abstract][Full Text] [Related]
99. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
Kakinuma H; Oi T; Hashimoto-Tsuchiya Y; Arai M; Kawakita Y; Fukasawa Y; Iida I; Hagima N; Takeuchi H; Chino Y; Asami J; Okumura-Kitajima L; Io F; Yamamoto D; Miyata N; Takahashi T; Uchida S; Yamamoto K
J Med Chem; 2010 Apr; 53(8):3247-61. PubMed ID: 20302302
[TBL] [Abstract][Full Text] [Related]
100. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans.
Akabane T; Tanaka K; Irie M; Terashita S; Teramura T
Xenobiotica; 2011 May; 41(5):372-84. PubMed ID: 21385103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
